Sign in
Taking peopleNo phase

Effects of Stellate Ganglion Block on Delirium and Circadian Rhythm in Geriatric Intensive Care Patients

Key facts

Who runs it
Antalya Training and Research Hospital
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
130 people, planned
Started
6 Aug 2026
Expected to end
1 Feb 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • stellate ganglion block with 0.5% bupivacaine
  • Placebo Injection
Record updated
22 September 2026

Who can take part

Age
65 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • Patients aged 65 years or older expected to remain in the intensive care unit for more than 48 hours
  • RASS score > -4

Who cannot take part

  • History of neurodegenerative disease (e.g., Alzheimer's disease, dementia, vascular dementia)
  • Uncontrolled psychiatric disorders
  • Alcohol use disorder and/or substance abuse
  • History of traumatic brain injury or ischemic/hemorrhagic cerebrovascular event
  • Severe hearing and/or visual impairment
  • Renal failure (Acute Kidney Injury stage 2-3) and/or liver failure
  • Contraindications to stellate ganglion block (e.g., coagulopathy, glaucoma, recent myocardial infarction)
  • Allergy to bupivacaine
  • Benzodiazepine use
  • Beta-blocker use
  • Sepsis
  • Inability to communicate in Turkish or English
  • Severe hyponatremia
  • Hemodynamic instability

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Stellate ganglion block

This trial is currently available in Türkiye.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Delirium is a common complication in elderly intensive care unit (ICU) patients and is associated with poor clinical outcomes. Circadian rhythm disruption is considered an important contributing factor in delirium development. Stellate ganglion block (SGB) may modulate autonomic nervous system activity and improve circadian rhythm regulation.

Read full original descriptionShow less

This prospective randomized placebo-controlled trial aims to evaluate the effects of ultrasound-guided stellate ganglion block on delirium incidence and circadian rhythm in ICU patients aged 65 years and older. Delirium will be assessed using validated clinical scales, and circadian rhythm will be evaluated through serial measurements of serum melatonin and plasma cortisol levels

The 2 groups in the trial

  • Placebo GroupPlacebo, for comparison

    Ultrasound-guided intramuscular injection of 2 mL normal saline to the anterolateral cervical region

    Treatment: Placebo Injection

  • Stellate Ganglion Block GroupTreatment being tested

    Ultrasound-guided stellate ganglion block using 5 mL of 0.5% bupivacaine

    Treatment: stellate ganglion block with 0.5% bupivacaine

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Stellate Ganglion Block on Delirium and Circadian Rhythm in Geriatric Intensive Care Patients: A Prospective Randomized Controlled Trial
Criteria questions
Built from NCT07558642, who can take part
Record updated
22 September 2026